Free Trial
NASDAQ:ABVC

ABVC BioPharma (ABVC) Stock Price, News & Analysis

ABVC BioPharma logo
$0.57 +0.04 (+7.58%)
(As of 11/20/2024 ET)

About ABVC BioPharma Stock (NASDAQ:ABVC)

Key Stats

Today's Range
$0.55
$0.57
50-Day Range
$0.47
$0.74
52-Week Range
$0.41
$2.45
Volume
27,939 shs
Average Volume
234,020 shs
Market Capitalization
$7.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

ABVC BioPharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
15th Percentile Overall Score

ABVC MarketRank™: 

ABVC BioPharma scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for ABVC BioPharma.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ABVC BioPharma is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ABVC BioPharma is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ABVC BioPharma has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.77% of the float of ABVC BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    ABVC BioPharma has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ABVC BioPharma has recently increased by 34.83%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    ABVC BioPharma does not currently pay a dividend.

  • Dividend Growth

    ABVC BioPharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.77% of the float of ABVC BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    ABVC BioPharma has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ABVC BioPharma has recently increased by 34.83%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    ABVC BioPharma has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for ABVC BioPharma this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, ABVC BioPharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.90% of the stock of ABVC BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 11.38% of the stock of ABVC BioPharma is held by institutions.

  • Read more about ABVC BioPharma's insider trading history.
Receive ABVC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter.

ABVC Stock News Headlines

My #1 Pre IPO Trade for 2025 – NAME and TICKER
One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...
See More Headlines

ABVC Stock Analysis - Frequently Asked Questions

ABVC BioPharma's stock was trading at $1.16 at the start of the year. Since then, ABVC shares have decreased by 51.1% and is now trading at $0.5674.
View the best growth stocks for 2024 here
.

ABVC BioPharma, Inc. (NASDAQ:ABVC) released its quarterly earnings data on Monday, April, 3rd. The company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($1.90) by $0.40. The business had revenue of $0.59 million for the quarter, compared to the consensus estimate of $0.03 million. ABVC BioPharma had a negative net margin of 1,619.65% and a negative trailing twelve-month return on equity of 104.94%.

ABVC BioPharma's stock reverse split on Tuesday, July 25th 2023. The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

ABVC BioPharma (ABVC) raised $7 million in an initial public offering on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at $6.25 per share.

Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that ABVC BioPharma investors own include Meta Platforms (META), NIO (NIO), ObsEva (OBSV), Tesla (TSLA), Alibaba Group (BABA), ChargePoint (CHPT) and Walt Disney (DIS).

Company Calendar

Last Earnings
4/03/2023
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABVC
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Net Income
$-10,520,000.00
Net Margins
-1,619.65%
Pretax Margin
-1,699.98%

Debt

Sales & Book Value

Annual Sales
$150,000.00
Book Value
$1.02 per share

Miscellaneous

Free Float
11,431,000
Market Cap
$7.36 million
Optionable
Not Optionable
Beta
0.82
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:ABVC) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners